
Opinion|Videos|April 22, 2024
HER2-Targeted Therapy in Upper GI Cancer
Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
Advertisement
Advertisement
Related to this article

“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.

ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

Variation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture.
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
2
Rezatapopt Shows Durable Responses in TP53 Y220C-Mutated PROC
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
5

